[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.22. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 13, 1962

Socialized Advertising

JAMA. 1962;182(2):35-37. doi:10.1001/jama.1962.03050410131045

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

Congress may give the federal government power virtually to dictate copy for drug advertising, Pharmaceutical Manufacturers Association President Austin Smith told members of the Pharmaceutical Advertising Club in New York Sept. 20.

He said three proposed bills would stringently regulate the wording and display of medical journal advertising.

The Dingell bill, H.R. 6471, introduced in the House April 19, 1961, provides, he said, that "an advertisement of a prescription drug shall be deemed to be misleading in a material respect if such an advertisement fails to contain a conspicuous and truthful disclosure of (1) the quantitative formula of the drug with each active ingredient listed by its common or usual name, (2) the side effects of the drug, and (3) the contraindications of the drug."

A second bill, H.R. 11581, the socalled Administration bill introduced by Congressman Oren Harris May 3, 1962, goes further, providing in addition that ads must

First Page Preview View Large
First page PDF preview
First page PDF preview
×